INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 43h ago
HOUSE PTR3h ago
SEC 13F3h ago
ROBINHOOD CHAIN3h ago
SEC FORM 4/Grant or awardVerified data

Perl Jessica reported EBS

SVP, General Counsel, Corp Sec · Emergent BioSolutions Inc. · Emergent BioSolutions Inc. — Employee Stock Option (Right to buy)

Side
A
Value
—
Shares
46.7K
Price
—
Executed
Mar 3, 2026
Disclosed
Mar 5, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Mar 3 executedMar 5, 2026 disclosed

EBS · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 48.7% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · EBS

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    GC
    Glessner ColeenEVP, Quality & Ethics, and CPL
    EBSEmergent BioSolutions Inc.
    Tax withholding
    		F$16K
    2,018 sh
    		Jun 8, 2026Jun 10, 2026
    traded Jun 8, 2026
    		+2dSEC FORM 4

    Evidence

    9
    WA
    Williams Paul AnthonySVP, Products Business
    EBSEmergent BioSolutions Inc.
    Tax withholding
    		F$5,552
    694 sh
    		Jun 8, 2026Jun 10, 2026
    traded Jun 8, 2026
    		+2dSEC FORM 4

    Evidence

    9
    HW
    Hartzel WilliamSVP, Bioservices
    EBSEmergent BioSolutions Inc.
    Tax withholding
    		F$14K
    1,741 sh
    		Jun 8, 2026Jun 10, 2026
    traded Jun 8, 2026
    		+2dSEC FORM 4

    Evidence

    21
    LC
    Lowry Simon CSVP, R&D, CMO
    EBSEmergent BioSolutions Inc.
    Grant or award
    		A—
    100.1K sh
    		Apr 29, 2026May 1, 2026
    traded Apr 29, 2026
    		+2dSEC FORM 4

    Evidence

    21
    GC
    Glessner ColeenEVP, Quality & Ethics, and CPL
    EBSEmergent BioSolutions Inc.
    Grant or award
    		A—
    100.1K sh
    		Apr 29, 2026May 1, 2026
    traded Apr 29, 2026
    		+2dSEC FORM 4

    Evidence

    21
    WA
    Williams Paul AnthonySVP, Products Business
    EBSEmergent BioSolutions Inc.
    Grant or award
    		A—
    100.1K sh
    		Apr 29, 2026May 1, 2026
    traded Apr 29, 2026
    		+2dSEC FORM 4

    Evidence

    21
    HW
    Hartzel WilliamSVP, Bioservices
    EBSEmergent BioSolutions Inc.
    Grant or award
    		A—
    100.1K sh
    		Apr 29, 2026May 1, 2026
    traded Apr 29, 2026
    		+2dSEC FORM 4

    Evidence

    21
    PJ
    Perl JessicaSVP, General Counsel, Corp Sec
    EBSEmergent BioSolutions Inc.
    Grant or award
    		A—
    104.3K sh
    		Apr 29, 2026May 1, 2026
    traded Apr 29, 2026
    		+2dSEC FORM 4

    Evidence

    16
    PJ
    Perl JessicaSVP, General Counsel, Corp Sec
    EBSEmergent BioSolutions Inc.
    Tax withholding
    		F$55K
    6,465 sh
    		Mar 5, 2026Mar 5, 2026
    traded Mar 5, 2026
    		+0dSEC FORM 4

    Evidence

    16
    LC
    Lowry Simon CSVP, R&D, CMO
    EBSEmergent BioSolutions Inc.
    Tax withholding
    		F$90K
    10.6K sh
    		Mar 5, 2026Mar 5, 2026
    traded Mar 5, 2026
    		+0dSEC FORM 4

    Evidence

    17
    LC
    Lowry Simon CSVP, R&D, CMO
    EBSEmergent BioSolutions Inc.
    Grant or award
    		A—
    44.8K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    16
    HW
    Hartzel WilliamSVP, Bioservices
    EBSEmergent BioSolutions Inc.
    Tax withholding
    		F$80K
    9,493 sh
    		Mar 5, 2026Mar 5, 2026
    traded Mar 5, 2026
    		+0dSEC FORM 4

    Evidence

    17
    HW
    Hartzel WilliamSVP, Bioservices
    EBSEmergent BioSolutions Inc.
    Grant or award
    		A—
    44.8K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    16
    WA
    Williams Paul AnthonySVP, Products Business
    EBSEmergent BioSolutions Inc.
    Tax withholding
    		F$79K
    9,397 sh
    		Mar 5, 2026Mar 5, 2026
    traded Mar 5, 2026
    		+0dSEC FORM 4

    Evidence

    17
    WA
    Williams Paul AnthonySVP, Products Business
    EBSEmergent BioSolutions Inc.
    Grant or award
    		A—
    44.8K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    16
    GC
    Glessner ColeenEVP, Quality & Ethics, and CPL
    EBSEmergent BioSolutions Inc.
    Tax withholding
    		F$69K
    8,199 sh
    		Mar 5, 2026Mar 5, 2026
    traded Mar 5, 2026
    		+0dSEC FORM 4

    Evidence

    13
    GC
    Glessner ColeenEVP, Quality & Ethics, and CPL
    EBSEmergent BioSolutions Inc.
    Grant or award
    		A—
    44.8K sh
    		Mar 3, 2026Mar 5, 2026
    traded Mar 3, 2026
    		+2dSEC FORM 4

    Evidence

    9
    GC
    Glessner ColeenEVP, Quality & Ethics, and CPL
    EBSEmergent BioSolutions Inc.
    Tax withholding
    		F$31K
    2,852 sh
    		Feb 6, 2026Feb 10, 2026
    traded Feb 6, 2026
    		+4dSEC FORM 4

    Evidence

    23
    GC
    Glessner ColeenEVP, Quality & Ethics, and CPL
    EBSEmergent BioSolutions Inc.
    Disposition to issuer
    		D$315K
    28.8K sh
    		Feb 6, 2026Feb 10, 2026
    traded Feb 6, 2026
    		+4dSEC FORM 4

    Evidence

    9
    PJ
    Perl JessicaSVP, General Counsel, Corp Sec
    EBSEmergent BioSolutions Inc.
    Tax withholding
    		F$10K
    918 sh
    		Feb 9, 2026Feb 10, 2026
    traded Feb 9, 2026
    		+1dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0002043716-26-000005
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Mar 3, 2026
    Published
    Mar 5, 2026
    Ingested by INSIDER
    Nov 5, 04:13 UTC
    Last re-read
    Nov 5, 04:13 UTC

    Extracted facts

    Filer
    Perl Jessica
    Role
    SVP, General Counsel, Corp Sec
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Emergent BioSolutions Inc. — Employee Stock Option (Right to buy)
    Ticker
    EBS
    Shares
    46.7K
    Price per share
    $0
    Execution date (reported)
    Mar 3, 2026
    Owned after transaction
    142.6K shares
    Days from execution to publication
    2

    What this establishes

    Perl Jessica filed this Form 4 reporting a grant or award of EBS on Mar 3, 2026. It became public on Mar 5, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    SVP, General Counsel, Corp Sec
    Perl Jessicacik:0002043716
    Issuer
    Emergent BioSolutions Inc.cik:0001367644

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.